for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tyme Technologies Inc

TYME.OQ

Latest Trade

1.14USD

Change

-0.03(-2.56%)

Volume

430,712

Today's Range

1.12

 - 

1.17

52 Week Range

0.85

 - 

4.98

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.17
Open
1.16
Volume
430,712
3M AVG Volume
168.49
Today's High
1.17
Today's Low
1.12
52 Week High
4.98
52 Week Low
0.85
Shares Out (MIL)
172.21
Market Cap (MIL)
196.32
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q1 2022 Tyme Technologies Inc Earnings Release

Latest Developments

More

Tyme Technologies Inc Reports Fiscal Year 2021 Financial Results

Tyme Announces Richie Cunningham As New Chief Executive Officer

Tyme Technologies Inc Says On November 23, Appointed Richard Cunningham As New CEO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Tyme Technologies Inc

TYME Technologies, Inc. is a biotechnology company. The Company is focused on developing cancer metabolism-based therapies (CMBTsTM) for solid tumors and hematologic cancers. The Company’s lead clinical CMBT compound, SM-88, is an oral investigational modified tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. SM-88 is an orally administered cancer metabolism-based therapy that is chemically altered to be non-functional for fundamental tumor cell processes, including protein synthesis. The Company has multiple cancer metabolism-based assets and other formulations for SM-88 in the pipeline, including injectable, intranasal, and transdermal that are expected to be advanced into the clinical setting.

Industry

Biotechnology & Drugs

Contact Info

1 PLUCKEMIN WAY - SUITE 103

BEDMINSTER, NJ

07921

United States

+1.212.4612315

https://www.tymeinc.com/

Executive Leadership

Steve Hoffman

Chairman of the Board, Chief Scientific Officer

Richard Cunningham

Chief Executive Officer, Director

Frank L. Porfido

Chief Financial Officer

John Rothman

Executive Vice President of Product Development

Jonathan Eckard

Chief Business Officer

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.93
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-45.09
Return on Equity (TTM)
-41.47

Latest News

Latest News

BRIEF-Tyme-18 Demonstrates Anti-Cancer Effect In New Preclinical Data Presented At AACR 2020

* TYME-18 DEMONSTRATES ANTI-CANCER EFFECT IN NEW PRECLINICAL DATA PRESENTED AT AACR 2020

BRIEF-Tyme Presents New Preclinical Data Supporting SM-88 Mechanism Of Action At AACR 2020

* TYME PRESENTS NEW PRECLINICAL DATA SUPPORTING SM-88 MECHANISM OF ACTION AT AACR 2020

BRIEF-Tyme Announces Q4 And Fiscal Year 2020 Financial And Operating Results

* TYME ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2020 FINANCIAL AND OPERATING RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up